Daily Data as of 7/17/2018
|Closing Market Price||$20.08|
|Common Shares Outstanding||22,212,361|
|52 Week Average Premium/Discount||-2.59%|
|52 Week High/Low Market Price||$|
|52 Week High/Low Market NAV||$|
|Current Distribution Rate||9.15%|
|Quarterly Dividend Per Share||$0.4300|
|Ex-Dividend Date||May 31, 2018|
|Payable Date||June 29, 2018|
Current quarter’s distribution per share annualized; divided by the June 29, 2018 market price per share. The Fund’s second quarter 2018 distributions were comprised of long-term capital gains. The distribution rate alone is not indicative of Fund performance. To the extent that any portion of the current distributions were estimated to be sourced from something other than income, such as return of capital, the source would have been disclosed in a Section 19(a) Notice located under the “Investor Information” section of the Fund’s website. Please note that the distribution classifications are preliminary and certain distributions may be re-classified at year end. Please refer to year-end tax documents for the final classifications of the Fund’s distributions for a given year.
Tekla Life Sciences Investors ("HQL") is a non-diversified closed-end healthcare fund traded on the New York Stock Exchange under the ticker HQL. HQL primarily invests in the life sciences (including biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies), agriculture and environmental management industries. The Fund's objective is to provide long-term capital appreciation through investments in companies in the life sciences industry believed to have significant potential for above-average long-term growth. Selection will emphasize the smaller, emerging companies with a maximum of 40% of the Fund's assets in restricted securities of both public and private companies. Management believes this provides a unique opportunity not usually available to mutual fund investors.